AG˹ٷ

STOCK TITAN

[8-K] Reviva Pharmaceuticals Holdings, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Reviva Pharmaceuticals Holdings, Inc. furnished a Current Report on Form 8-K stating it issued a press release on August 14, 2025 that discloses financial information and operating metrics for the fiscal quarter ended June 30, 2025 and discusses business outlook. The filing indicates the press release is attached as Exhibit 99.1 and is incorporated by reference into the report. The company also states the information is being furnished to the SEC and expressly is not being "filed" for purposes of Exchange Act Section 18, limiting the legal liabilities associated with formal filed disclosures.

Reviva Pharmaceuticals Holdings, Inc. ha presentato un Current Report sul Modulo 8-K, comunicando di aver diffuso un comunicato stampa il 14 agosto 2025 che fornisce informazioni finanziarie e metriche operative relative al trimestre fiscale chiuso il 30 giugno 2025 e illustra le prospettive aziendali. Nel deposito si specifica che il comunicato è allegato come Exhibit 99.1 e viene incorporato per riferimento nel rapporto. La società precisa inoltre che tali informazioni sono fornite alla SEC e non vengono espressamente "filed" ai fini della Sezione 18 dell'Exchange Act, limitando così le responsabilità legali connesse a divulgazioni formalmente depositate.

Reviva Pharmaceuticals Holdings, Inc. presentó un Current Report en el Formulario 8-K informando que emitió un comunicado de prensa el 14 de agosto de 2025 que revela información financiera y métricas operativas del trimestre fiscal concluido el 30 de junio de 2025 y comenta la perspectiva del negocio. El envío indica que el comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en el informe. La compañía también afirma que la información se está proporcionando a la SEC y que expresamente no se está "filed" para fines de la Sección 18 del Exchange Act, limitando las responsabilidades legales asociadas con divulgaciones formalmente presentadas.

Reviva Pharmaceuticals Holdings, Inc.� Form 8-K� Current Report� 제출하면� 2025� 8� 14일자� 2025� 6� 30일로 종료� 회계분기 동안� 재무 정보 � 운영 지표를 공개하고 기업 전망� 설명하는 보도자료� 발표했음� 알렸습니�. 제출서류에는 해당 보도자료가 Exhibit 99.1� 첨부되어 보고서에 참조� 편입되어 있다� 명시되어 있습니다. 회사� 또한 � 정보가 SEC� 제공되는 것이� Exchange Act �18조의 목적� 명시적으� "filed"되는 것이 아니라고 밝혀 공식적으� 제출� 공시와 관련된 법적 책임� 제한한다� 덧붙였습니�.

Reviva Pharmaceuticals Holdings, Inc. a déposé un Current Report sur le formulaire 8-K indiquant qu'elle a publié un communiqué de presse le 14 août 2025 divulguant des informations financières et des indicateurs opérationnels pour le trimestre clos le 30 juin 2025 et exposant les perspectives commerciales. Le dépôt précise que le communiqué est annexé en tant que Exhibit 99.1 et est incorporé par référence au rapport. La société indique également que ces informations sont fournies à la SEC et ne sont pas expressément "filed" au sens de la Section 18 de l'Exchange Act, ce qui limite les responsabilités juridiques liées aux divulgations formelles déposées.

Reviva Pharmaceuticals Holdings, Inc. reichte einen Current Report auf Formular 8-K ein und teilte mit, dass am 14. August 2025 eine Pressemitteilung veröffentlicht wurde, die finanzielle Informationen und operative Kennzahlen für das am 30. Juni 2025 endende Quartal sowie Angaben zur Geschäftsentwicklung enthält. In der Einreichung wird angegeben, dass die Pressemitteilung als Exhibit 99.1 beigefügt und durch Verweis in den Bericht aufgenommen ist. Das Unternehmen erklärt außerdem, dass die Informationen der SEC zur Verfügung gestellt werden und ausdrücklich nicht im Sinne des Exchange Act Section 18 "filed" werden, wodurch die Haftung im Zusammenhang mit formell eingereichten Offenlegungen eingeschränkt wird.

Positive
  • Press release issued disclosing financial information and operating metrics for the quarter ended June 30, 2025
  • Exhibit 99.1 furnished with the 8-K, signaling timely disclosure of quarter results
  • Explicit statement that information is furnished to the SEC, aligning with disclosure procedures
Negative
  • The 8-K text does not include the underlying financial figures or operating metrics (those are in Exhibit 99.1)
  • Information is furnished, not filed, which limits statutory Section 18 liability and may affect incorporation into later filings

Insights

TL;DR: Company furnished a results press release for the quarter ended June 30, 2025; the 8-K itself contains no numeric financial data.

The filing notifies investors that a press release containing quarter-end financials and operating metrics was issued and is attached as Exhibit 99.1. Because the registrant states the information is "furnished" rather than "filed," the 8-K limits statutory liability for the disclosed content. From an analytical standpoint, this is a routine disclosure mechanism to distribute quarterly results outside of a formal 10-Q amendment or proxy filing. Materiality depends entirely on the content of Exhibit 99.1, which is not included in this text. The 8-K confirms timeliness of disclosure but does not by itself allow assessment of revenue, profit, or cash metrics.

TL;DR: The company followed Regulation FD and SEC furnishing practice; legal exposure is limited by furnishing language.

This Form 8-K documents a Regulation FD-style disclosure: a press release was furnished and incorporated as an exhibit. The filing explicitly states the exhibit is furnished and not filed, which is a standard governance/legal approach to control incorporation and liability under the federal securities laws. The document also references Regulation FD (Items 2.02 and 7.01), indicating the company is meeting public disclosure obligations. No governance or management changes, related-party transactions, or remediation actions are described in this filing.

Reviva Pharmaceuticals Holdings, Inc. ha presentato un Current Report sul Modulo 8-K, comunicando di aver diffuso un comunicato stampa il 14 agosto 2025 che fornisce informazioni finanziarie e metriche operative relative al trimestre fiscale chiuso il 30 giugno 2025 e illustra le prospettive aziendali. Nel deposito si specifica che il comunicato è allegato come Exhibit 99.1 e viene incorporato per riferimento nel rapporto. La società precisa inoltre che tali informazioni sono fornite alla SEC e non vengono espressamente "filed" ai fini della Sezione 18 dell'Exchange Act, limitando così le responsabilità legali connesse a divulgazioni formalmente depositate.

Reviva Pharmaceuticals Holdings, Inc. presentó un Current Report en el Formulario 8-K informando que emitió un comunicado de prensa el 14 de agosto de 2025 que revela información financiera y métricas operativas del trimestre fiscal concluido el 30 de junio de 2025 y comenta la perspectiva del negocio. El envío indica que el comunicado se adjunta como Exhibit 99.1 y se incorpora por referencia en el informe. La compañía también afirma que la información se está proporcionando a la SEC y que expresamente no se está "filed" para fines de la Sección 18 del Exchange Act, limitando las responsabilidades legales asociadas con divulgaciones formalmente presentadas.

Reviva Pharmaceuticals Holdings, Inc.� Form 8-K� Current Report� 제출하면� 2025� 8� 14일자� 2025� 6� 30일로 종료� 회계분기 동안� 재무 정보 � 운영 지표를 공개하고 기업 전망� 설명하는 보도자료� 발표했음� 알렸습니�. 제출서류에는 해당 보도자료가 Exhibit 99.1� 첨부되어 보고서에 참조� 편입되어 있다� 명시되어 있습니다. 회사� 또한 � 정보가 SEC� 제공되는 것이� Exchange Act �18조의 목적� 명시적으� "filed"되는 것이 아니라고 밝혀 공식적으� 제출� 공시와 관련된 법적 책임� 제한한다� 덧붙였습니�.

Reviva Pharmaceuticals Holdings, Inc. a déposé un Current Report sur le formulaire 8-K indiquant qu'elle a publié un communiqué de presse le 14 août 2025 divulguant des informations financières et des indicateurs opérationnels pour le trimestre clos le 30 juin 2025 et exposant les perspectives commerciales. Le dépôt précise que le communiqué est annexé en tant que Exhibit 99.1 et est incorporé par référence au rapport. La société indique également que ces informations sont fournies à la SEC et ne sont pas expressément "filed" au sens de la Section 18 de l'Exchange Act, ce qui limite les responsabilités juridiques liées aux divulgations formelles déposées.

Reviva Pharmaceuticals Holdings, Inc. reichte einen Current Report auf Formular 8-K ein und teilte mit, dass am 14. August 2025 eine Pressemitteilung veröffentlicht wurde, die finanzielle Informationen und operative Kennzahlen für das am 30. Juni 2025 endende Quartal sowie Angaben zur Geschäftsentwicklung enthält. In der Einreichung wird angegeben, dass die Pressemitteilung als Exhibit 99.1 beigefügt und durch Verweis in den Bericht aufgenommen ist. Das Unternehmen erklärt außerdem, dass die Informationen der SEC zur Verfügung gestellt werden und ausdrücklich nicht im Sinne des Exchange Act Section 18 "filed" werden, wodurch die Haftung im Zusammenhang mit formell eingereichten Offenlegungen eingeschränkt wird.

false 0001742927 0001742927 2025-08-14 2025-08-14 0001742927 rvph:CommonStockParValue00001PerShareCustomMember 2025-08-14 2025-08-14 0001742927 rvph:WarrantsToPurchaseOneShareOfCommonStockCustomMember 2025-08-14 2025-08-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT 
 
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934 
 
Date of Report (Date of earliest event reported): August 14, 2025
 
REVIVA PHARMACEUTICALS HOLDINGS, INC.
(Exact name of registrant as specified in its charter)
 
Delaware
 
001-38634
 
85-4306526
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(IRS Employer
Identification No.)
 
10080 N Wolfe Road, Suite SW3-200, Cupertino, CA
 
95014
(Address of principal executive offices)
 
(Zip Code)
 
Registrant’s telephone number, including area code: (408) 501-8881
 
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act.
 
Title of each class
 
Trading Symbol(s)
 
Name of each exchange on which
registered
Common Stock, par value $0.0001 per share
 
RVPH
 
Nasdaq Capital Market
Warrants to purchase one share of Common Stock
 
RVPHW
 
Nasdaq Capital Market
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
Emerging growth company
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
 

 
 
Item 2.02.
Results of Operations and Financial Condition.
 
Reviva Pharmaceuticals Holdings, Inc. (the “Company”) issued a press release on August 14, 2025, disclosing financial information and operating metrics for its fiscal quarter ended June 30, 2025 and discussing its business outlook. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
 
Item 7.01.
Regulation FD Disclosure.
 
See “Item 2.02 Results of Operations and Financial Condition” above.
 
The information in this Current Report on Form 8-K under Items 2.02 and 7.01, including the information contained in Exhibit 99.1, is being furnished to the Securities and Exchange Commission, and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by a specific reference in such filing.
 
Item 9.01.
Financial Statements and Exhibits.
 
(d) Exhibits.
 
The following Exhibit 99.1 is furnished with this report:
 
Exhibit No.
 
Description
99.1
 
Press Release issued by Reviva Pharmaceuticals Holdings, Inc., dated August 14, 2025.
104
 
Cover Page Interactive Data File (embedded within the Inline XBRL document)
 
 

 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
REVIVA PHARMACEUTICALS HOLDINGS, INC.
 
       
Dated: August 14, 2025
By:
/s/ Narayan Prabhu
 
 
Name:
Title:
Narayan Prabhu
Chief Financial Officer
 
 
 
 
 

FAQ

What did Reviva Pharmaceuticals (RVPH) disclose in this Form 8-K?

The company disclosed it issued a press release on August 14, 2025 containing financial information and operating metrics for the fiscal quarter ended June 30, 2025, and attached that press release as Exhibit 99.1.

Does this 8-K include the actual financial numbers for Q2 2025?

No. The 8-K states a press release with financial information was furnished as Exhibit 99.1; the numeric financials are not contained in the 8-K text provided here.

Is the information in this Form 8-K considered "filed" with the SEC?

No. The filing explicitly states the information and Exhibit 99.1 are being furnished to the SEC and shall not be deemed "filed" for purposes of Section 18 of the Exchange Act.

Which Items of the Form 8-K are referenced?

The filing references Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure) and indicates Exhibit 99.1 is incorporated by reference into those items.

Where can investors find the detailed financial metrics mentioned?

The detailed financial metrics and operating information are contained in the press release attached as Exhibit 99.1, which should be available on the company’s SEC filings page or investor relations site.
Reviva Pharmaceutcls Hldgs Inc

NASDAQ:RVPH

RVPH Rankings

RVPH Latest News

RVPH Latest SEC Filings

RVPH Stock Data

31.28M
63.06M
10.3%
23.64%
8.9%
Biotechnology
Pharmaceutical Preparations
United States
CUPERTINO